Delving into the Latest Updates on PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms-

Target

PD-1

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Extensive stage Small Cell Lung CancerSquamous cell carcinoma of head and neck metastatic

Inactive Indication-

Originator Organization

Sichuan Baili Pharmaceuticals Co.,Ltd

Active Organization

Sichuan Baili Pharmaceuticals Co.,Ltd

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study is a multicenter, open-label, phase II clinical study to explore the safety and efficacy of BL-M07D1+PD-1 monoclonal antibody and BL-M07D1+PD-1 monoclonal antibody+ capecitabine in patients with unresectable locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Start Date01 Oct 2024

Sponsor / Collaborator

Sichuan Baili Pharmaceuticals Co.,Ltd

[+1]

NCT06475300 / RecruitingPhase 2

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors.

Start Date25 Jun 2024

Sponsor / Collaborator

Sichuan Baili Pharmaceuticals Co.,Ltd

[+1]

NCT06437509 / RecruitingPhase 2

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.

Start Date13 Jun 2024

Sponsor / Collaborator

Sichuan Baili Pharmaceuticals Co.,Ltd

[+1]

100 Clinical Results associated with PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical)

Login to view more data

100 Translational Medicine associated with PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical)

Login to view more data

100 Patents (Medical) associated with PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical)

Login to view more data

100 Deals associated with PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Extensive stage Small Cell Lung Cancer	Phase 2	CN	Sichuan Baili Pharmaceuticals Co.,Ltd	13 Jun 2024
Squamous cell carcinoma of head and neck metastatic	Phase 2	CN	Sichuan Baili Pharmaceuticals Co.,Ltd	07 Jun 2024